Genetic obesity is associated with increased neuropeptide Y (NPY) messenger RNA (mRNA) and decreased POMC mRNA in the hypothalamus of ob/ob and db/db mice, or impaired sensitivity to ␣MSH (derived from POMC) in the yellow agouti mouse. Acquired obesity can be produced by chemically lesioning the hypothalamus with either monosodium glutamate (MSG) in neonates or gold thioglucose (GTG) in adult mice. The present study examined whether elevated NPY mRNA and/or decreased POMC mRNA in the hypothalamus are associated with obesity due to hypothalamic lesions. GTG injection into adult mice produced a profound obese phenotype, including hyperphagia, increased body weight, and increased leptin mRNA and peptide, in association with reduced hypothalamic NPY mRNA and POMC mRNA. MSG treatment produced virtual elimination of NPY mRNA in the arcuate nucleus and a reduction of hypothalamic POMC mRNA, and led to elevated leptin. MSG pretreatment did not attenuate GTG-induced hyperphagia and obese phenotype. These results do not support a role for NPY-synthesizing neurons in the arcuate nucleus in mediating hypothalamic acquired obesity, but are consistent with the hypothesis that decreased activity of hypothalamic neurons synthesizing POMC play a role in mediating hypothalamic obesity. (Endocrinology 139: [4483][4484][4485][4486][4487][4488] 1998) 
perphagia, increased body weight, and increased leptin mRNA and peptide, in association with reduced hypothalamic NPY mRNA and POMC mRNA. MSG treatment produced virtual elimination of NPY mRNA in the arcuate nucleus and a reduction of hypothalamic POMC mRNA, and led to elevated leptin. MSG pretreatment did not attenuate GTG-induced hyperphagia and obese phenotype. These results do not support a role for NPY-synthesizing neurons in the arcuate nucleus in mediating hypothalamic acquired obesity, but are consistent with the hypothesis that decreased activity of hypothalamic neurons synthesizing POMC play a role in mediating hypothalamic obesity. (Endocrinology 139: [4483] [4484] [4485] [4486] [4487] [4488] 1998) E LEVATED synthesis of neuropeptide Y (NPY) in the arcuate nucleus has been proposed to play an important role in mediating the obese phenotype in genetically obese animals (1, 2) . This hypothesis is widely viewed as credible because 1) experimental elevation of hypothalamic NPY can induce obesity (1); 2) in some forms of genetic obesity, NPY messenger RNA (mRNA) in the arcuate nucleus is elevated (3-6); 3) leptin inhibits NPY mRNA in the arcuate nucleus (3, 7) ; and 4) obesity is attenuated in leptindeficient ob/ob mice that lack NPY (8) . On the other hand, reduced POMC activity is also implicated in obesity, as 1) obesity in yellow agouti mice is associated with interference in response to ␣MSH, which is derived from POMC (9 -13); 2) genetic deletion of an ␣MSH receptor produces obesity (14) ; 3) central administration of ␣MSH or a melanocortin-4 receptor agonist inhibits food intake, whereas a melanocortin-4 receptor antagonist stimulates food intake (13, 15) ; and 4) the expression of hypothalamic POMC mRNA is reduced in genetically obese ob/ob and db/db mice and is stimulated by leptin (16 -18) .
Obesity can be acquired through several perturbations, including hypothalamic damage. Hypothalamic obesity has been reported in humans (19) as well as in other species, for example after neonatal administration of monosodium glutamate (MSG) (20) or treatment of adult mice with gold thioglucose (GTG) (21) . An ip injection of GTG produces a lesion in the ventromedial hypothalamus whose localization is reproducible and which recapitulates the severe obese phenotype characteristic of lesions of the hypothalamic ventromedial nucleus produced by other means (e.g. an electrical current, an excitotoxin, or a tumor). Therefore, GTG has been used as a powerful tool to assess mechanisms of hypothalamic obesity (22) (23) (24) (25) (26) (27) (28) (29) (30) (31) (32) . The hypothalamic lesion produced by GTG is dependent on insulin and the glucose moiety of the GTG molecule and is blocked by glucose uptake inhibitors, so GTG has been thought to primarily target the glucosesensitive neurons of the hypothalamus (21, 33) . This hypothesis was supported by the observation that mice with GTG lesions are insensitive to the satiety effects of glucose and the induction of feeding by 2-deoxyglucose, but are sensitive to the satiety effects of cholecystokinin (34) . The present study examined whether increased hypothalamic NPY mRNA and/or decreased hypothalamic POMC mRNA are associated with GTG-or MSG-induced hypothalamic obesity.
Materials and Methods

Animals and tissues
Adult mice (C57BL/6J) were bred in the institutional animal facility. On postnatal day 4, pups were given a single injection of either saline (Sal) or MSG (4 mg/g BW). The mice were weaned at 3 weeks, and 2 months later were weighed and then injected ip with either GTG (0.8 mg/g BW) or Sal for a total of four groups (Sal/Sal, Sal/GTG, MSG/Sal, and MSG/GTG). Groups were balanced to have approximately equal distributions of gender (Sal/Sal, four males and five females; Sal/GTG, three males and five females; MSG/Sal, three males and four females; MSG/GTG, three males and seven females; numbers reflect final distributions in each group after exclusion of GTG-injected mice that died, showed persistent toxic effects, or failed to exhibit GTG-induced lesions or obesity); in the final data analysis there was no effect of gender, so the two genders were pooled for each group. Before injection of GTG, the initial body weights of the four groups were (mean Ϯ sem, in grams): Sal/Sal, 21.9 Ϯ 1.4; Sal/GTG, 22.4 Ϯ 1.4; MSG/Sal, 22.7 Ϯ 1.4; and MSG/GTG, 20.8 Ϯ 1. There was no difference between the groups in initial (pre-GTG) body weight. After injection of GTG or saline, the mice were housed individually, and daily food intake was measured. Mice that died or showed toxic effects in response to GTG (for example, body weight loss that persisted for more than 4 days after the GTG injection; n ϭ 9) and mice in which GTG failed to produce an observable lesion (correlated with development of obesity) were excluded from the study. Mice were weighed at regular intervals and were killed 2 weeks after GTG (or saline) injection. Mice were killed by carbon dioxide asphyxiation and decapitated, and their brains were rapidly removed and frozen with powdered dry ice. The brains were kept frozen at Ϫ70 C until sectioned (10 m) on a cryostat.
In situ hybridization
NPY in situ hybridization was carried out as described previously (35) , and POMC in situ hybridization used the same methods, but with a probe generated using PCR and the following oligonucleotides: Nterminal primer, 5Ј-CCTGTGAAGGTGTACCCCAATGTC-3Ј; and C-terminal primer, 5Ј-CACGTTCTTGATGATGGCGTTC-3Ј. Frozen coronal sections (10 m thick) through the mouse hypothalamus were thaw-mounted onto subbed slides, fixed in 4% paraformaldehyde in 0.1 m phosphate buffer (pH 7.0) containing 0.03% diethylpyrocarbonate, dehydrated, and stored at Ϫ20 C until use. Representative sections through the hypothalamus were stained with cresyl violet, and sorting of the slides on the basis of histology was carried out to ensure that sections were matched for anterior-posterior level. Sections were prehybridized in 2 ϫ SSC (standard saline citrate), 5 mm EDTA, 2.5 ϫ Denhardt's solution, 5 mm dithiothreitol, 100 mg/ml herring sperm DNA, 100 mg/ml yeast transfer RNA, 5 mg/ml single stranded calf thymus DNA, and 50% deionized formamide for 2 h at 42 C. Hybridization was carried out in the same buffer containing 10% dextran sulfate and labeled probe ( 32 P; 2 ϫ 10 6 dpm/20 l⅐section) at 42 C overnight. Sections (two sections per matched anterior-posterior level) were washed twice in 1 ϫ SSC for 15 min each time and in 0.1 ϫ SSC overnight at room temperature, followed by a final wash in 0.1 ϫ SSC for 1 h at 55 C. Slides were dehydrated, air-dried, and apposed to autoradiography film. After several exposures of the slides to film (2, 4, and 7 days), signal was quantified on an MCID system (Ontario, Canada). To quantify, a lens was used to magnify and capture the image of each brain, keeping magnification and lighting identical for the entire study. An area of constant size was placed over the region in the hypothalamus exhibiting signal, and the optical density of this region, subtracting out background, was determined by the MCID system. This corrected optical density was presumed to reflect the NPY or POMC mRNA. Cresyl violet-stained sections were also used to confirm the presence or absence of lesions under blinded conditions.
Northern blot analysis
Adipose tissue from the gonadal fat pad was removed, frozen with dry ice, and kept frozen at Ϫ70 C until Northern blot analysis was performed according to previously described protocols (36) , using the MCID system to quantify films. Serum was retained for measurement of leptin using a commercially available RIA kit (Linco Research, Inc., St. Charles, MO).
Statistical analysis
Two-way ANOVA followed by Newman-Keuls post-hoc test were used to determine significant differences between groups. P Ͻ 0.05 was considered significant.
Results
GTG lesion decreases hypothalamic NPY mRNA and POMC mRNA and leads to increased feeding, body weight, and leptin mRNA and peptide
In mice injected with saline as neonates and with GTG as adults, a hypothalamic lesion was observed that extended from the lateral arcuate nucleus through the ventrolateral aspect of the ventromedial nucleus (Fig. 1B) . The GTG lesion overlapped with the medial aspect of the distribution of both NPY and POMC mRNA (Fig. 2, A and B ), leading to a decrease in both mRNAs (P Ͻ 0.05; Fig. 3 , A and B, Sal/GTG vs. Sal/Sal). GTG had no detectable effect on NPY mRNA in dorsomedial nucleus, cortex, or other parts of the forebrain. GTG-injected mice became hyperphagic and exhibited a significant increase in body weight gain over the 2-week period following injection of GTG (P Ͻ 0.05; Fig. 3, C and D; FIG. 1. Photomicrographs of sections through the ventromedial hypothalamus demonstrating the lesions produced by GTG (B), MSG (C), and MSG and GTG (D) injected into the same mouse. A is taken from a mouse injected with saline neonatally and as an adult. MSG treatment results in an arcuate nucleus that appears sparsely populated with cells (compared with controls), whereas GTG produces a lesion in the ventromedial hypothalamus together with scar tissue that appears to encroach on the most dorsolateral aspect of the arcuate nucleus. In each of the photomicrographs, the third ventricle is seen along the left edge. Scale bar ϭ 100 m.
Sal/GTG vs. Sal/Sal), in association with significant increases in circulating levels of leptin and leptin mRNA (P Ͻ 0.05; Figs. 4 and 5).
MSG lesion decreases hypothalamic NPY mRNA and POMC mRNA and does not influence feeding or body weight, but leads to increased leptin mRNA and peptide
In mice injected with MSG as neonates and with saline as adults, a loss of neurons in the arcuate nucleus was observed, a lesion that was medial to the lesion produced by GTG (Fig.  1C) . The MSG lesion entirely overlapped the NPY mRNA distribution ( Fig. 2A) , thus essentially eliminating NPY mRNA in the hypothalamus; the amount of NPY mRNA detected was not significantly greater than background (P Ͼ 0.05; Fig. 3A) . MSG treatment had no detectable effect on NPY mRNA in cortex, dorsomedial nucleus, or other areas in the same section. The MSG lesion overlapped the medial aspect of the POMC mRNA distribution (Fig. 2B) , decreasing POMC mRNA by 72% (P Ͻ 0.05; Fig. 3B ). However, in contrast to NPY mRNA, POMC mRNA levels remained above background after the MSG lesion. In the mice injected with MSG as neonates and saline as adults (i.e. MSG/Sal), food intake and weight gain over a 2-week period were not significantly different from the food intake and weight gain of the saline-treated controls (Fig. 3, C 
Pretreatment with MSG does not prevent the GTG-induced increased feeding and body weight, and further increased leptin mRNA and peptide
In mice injected with MSG as neonates and subsequently injected with GTG, loss of neurons in the arcuate nucleus was observed together with a lesion in the ventromedial hypothalamus (Fig. 1D) . As expected, the elimination of NPY mRNA in the arcuate by MSG was not altered by GTG, as NPY mRNA levels were not significantly above background after MSG treatment alone ( Fig. 2A) . In contrast, the combined lesions produced by MSG and GTG virtually eliminated both the medial and lateral aspects of the POMC mRNA field (Fig. 2B ), leading to significantly lower POMC mRNA in mice injected with both MSG and GTG than in mice injected with either MSG or GTG alone (P Ͻ 0.05; MSG/GTG vs. MSG/Sal and MSG/GTG vs. Sal/GTG; Fig. 3B ). Despite the elimination of NPY mRNA by treatment with MSG ( Figs.  2A and 3A) , the degree of hyperphagia and weight gain produced by the GTG lesion was not altered by pretreatment with MSG (P Ͻ 0.05; Fig. 3, C and D) . The induction of obesity by GTG in MSG-treated mice was also associated with increased circulating levels of leptin and leptin mRNA levels (P Ͻ 0.05; Figs. 4 and 5).
Discussion
Corroborating previous reports (21) , ip injection of GTG produced a profound obese phenotype, including hyperphagia and increased body weight concomitant with elevated leptin mRNA in adipose tissue and elevated plasma leptin (28) . The induction of obesity by GTG lesions was associated with decreased hypothalamic NPY and POMC mRNAs. Neonatal injection of MSG also produced elevated leptin mRNA in adipose tissue and elevated plasma leptin peptide. The increases in leptin mRNA and peptide observed in this study are consistent with previous studies which have directly demonstrated that adipose stores increase in association with obesity induced by both GTG (38) and MSG (39 -41) . Also in agreement with previous studies, MSG-injected mice did not exhibit hyperphagia or increased body weight (41) . MSG lesions virtually eliminated hypothalamic NPY mRNA and decreased hypothalamic POMC mRNA. Nevertheless, GTG injection resulted in similar hyperphagia, body weight gain, leptin mRNA, and leptin peptide regardless of whether the mice had been injected with MSG or saline as neonates. These data suggest that MSG treatment had no discernible effect on the obese phenotype produced by GTG.
Based on observations that elevated hypothalamic NPY is associated with several forms of obesity (1) (2) (3) (4) (5) , the present study assessed the hypothesis that obesity due to hypothalamic lesions is associated with elevation of hypothalamic NPY mRNA. As the virtual elimination of NPY mRNA by MSG had little or no effect on the obese phenotype produced FIG. 2 . In situ hybridization of NPY mRNA (A) and POMC mRNA (B) in sections through the ventromedial hypothalamus exposed to film, demonstrating the effects of GTG alone (Sal/GTG), MSG alone (MSG/Sal), and MSG followed by GTG injected into the same mouse (MSG/GTG). The first column (Sal/Sal) is taken from a mouse injected with saline neonatally and as an adult. The third ventricle is at the center of each image, flanked by the symmetric bilateral arcuate and ventromedial nuclei; the top of each image is just above the top of the third ventricle, and the lateral aspect of each image indicates the lateral extent of the brain section at this level.
by GTG, and GTG alone decreased NPY mRNA in the arcuate nucleus, these data suggest that NPY does not play a role in mediating GTG-induced obesity. Similarly, NPY appears to play little role in the increase in leptin and leptin mRNA exhibited by mice treated with MSG alone. Nevertheless, it is possible that NPY outside the arcuate nucleus (i.e. NPY cells not destroyed by MSG) may mediate some effects of the GTG lesion. For example, it has been reported that agouti obese mice exhibit an elevation of NPY mRNA in the dorsomedial nucleus (6) . However, this elevation of NPY mRNA in the dorsomedial nucleus only occurs after the development of obesity, and we have never observed an induction of NPY mRNA in the dorsomedial nucleus (or in any other part of the brain) in GTG-or MSG-treated mice. The hypothesis that NPY outside the arcuate nucleus mediates GTG-induced obesity could be tested by assessing whether NPY-deficient (knockout) mice develop obesity in response to GTG, but in any case most of the current data supporting a role for NPY in obesity are based on observations of NPY in the arcuate nucleus (1-3). Although NPY-deficient mice exhibit attenuated obesity in ob/ob mice (8), NPY-deficient mice have normal metabolic profiles and responses to leptin (42) . Thus, the present data are most plausibly interpreted to indicate that, in contrast to the obesity of leptin-deficient mice (8) , NPY plays little role in the profound obesity, including hyperphagia, exhibited by GTG-injected mice.
Based on observations that impaired synthesis of (16 -18) , processing of (43) , and sensitivity to (9 -14) hypothalamic POMC products are associated with several forms of obesity, the present study assessed the hypothesis that obesity due to hypothalamic lesions is associated with decreased hypothalamic POMC mRNA. The results demonstrated that both MSG and GTG reduce hypothalamic POMC mRNA in association with obesity. Therefore, the current data are consistent with the hypothesis that products derived from hypothalamic POMC may well play a role in both MSGinduced obesity and the more profound obesity produced by GTG. However, it is important to note that MSG and GTG produce anatomically distinct lesions, and therefore may not destroy the same POMC-producing neurons. The center of the MSG-induced lesion is in the periventricular region of the arcuate nucleus, whereas the center of the GTG-induced lesion is lateral to this region, although the lesions may overlap in the lateral portion of the arcuate nucleus. POMCproducing neurons extend from the arcuate nucleus into an area well lateral to the arcuate nucleus, a distribution similar to (but somewhat medial to) that of the GTG lesion. Therefore, MSG appears to destroy the medial extent of the POMC field, GTG appears to destroy the lateral extent, and the two lesions may overlap to destroy the same neurons in the center of the POMC field. This hypothesis is supported by the observation that POMC mRNA is maximally reduced only in the presence of both lesions (in contrast to NPY, which is maximally reduced by MSG alone, with or without GTG). Therefore, as GTG produces a more profound obesity, including hyperphagia, this analysis suggests that the lateral POMC field (largely spared by MSG) may be more important in the control of body weight and feeding than the medial POMC field. Such a hypothesis is consistent with the observation that the lateral POMC field appears to be more sensitive to fasting and leptin (18) .
As MSG and GTG both produce elevated leptin, suggesting leptin resistance, the present studies are consistent with the hypothesis that decreased activity of hypothalamic POMC neurons is associated with leptin resistance. Nevertheless, the POMC signaling system and the leptin system appear to be independent and additive (44) . This suggests that although decreased POMC mRNA may lead to obesity and elevated leptin levels, the obesity is not caused by leptin resistance. Instead, as has been demonstrated in agouti mice, obesity may lead to leptin resistance secondary to elevated leptin. Decreased POMC mRNA in the hypothalamus is also associated with obesity produced by the canine distemper virus (45) , obesity produced by deletion of the gene for the basic helix-loop-helix Nhlh2 transcription factor (46) , and obesity due to leptin deficiency and resistance (16 -18) . A recent report has demonstrated that mutations in the POMC gene can cause profound obesity in humans (47) . Together with those reports, the present study suggests that impairments in the synthesis, processing, or signaling of hypothalamic POMC products may be associated with many forms of both genetic and acquired obesity.
